Galapagos selected for Stoxx Europe 600 Index
MECHELEN, Belgium, Nov. 24, 2016 (GLOBE NEWSWIRE) -- Galapagos NV (Euronext & NASDAQ: GLPG) announces that Stoxx has selected Galapagos NV for inclusion in the Stoxx Europe 600 Index, effective 19 December 2016.
"After the inclusion of Galapagos in the BEL20 Index last March and, as first biotechnology company ever, in the AEX Index last June, we are pleased to be subsequently selected for inclusion in the Stoxx Europe 600 Index as well. The year 2016 has truly reflected the evolution of Galapagos from a pioneering target discovery company to an integrated biopharmaceutical powerhouse," says Onno van de Stolpe, CEO and Founder.
Stoxx Ltd. is a global index provider, currently calculating a global, comprehensive index family of over 7,500 strictly rules-based and transparent indices. Best known for the leading European equity indices EURO Stoxx 50, Stoxx Europe 50 and Stoxx Europe 600, Stoxx Ltd. maintains and calculates the Stoxx Global index family which consists of total market, broad and blue-chip indices for the regions Americas, Europe, Asia/Pacific and sub-regions Latin America and BRIC (Brazil, Russia, India and China) as well as global markets.[1]
About GalapagosGalapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises a pipeline of Phase 3, Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 480 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com.
Contacts
| Investors: | Media: |
| Elizabeth Goodwin | Evelyn Fox |
| VP IR &Corporate Communications+1 781 460 1784 | Director Communications +31 6 53 591 999 [email protected] |
| Paul van der HorstDirector IR & BusinessDevelopment+31 6 53 725 199 | |
| [email protected] |
Forward-looking statementsThis release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.
[1] Source: www.stoxx.com
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/07b312c6-b578-4d03-b8e2-2aaaa78ea2ee
Source: Galapagos NVSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Victory Home Remodeling Ranked Among Selling Power Magazine's Top 60 Best Places to Sell in America
- The Rock-It Company Expands to Abu Dhabi, Strengthening the Capital’s Position as a Global Hub for Luxury, Culture, and Major Events
- Xanvurleq Review: Can Xanvurleq AI Trading Platform Simplify Crypto Trading?
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
BRICSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share